ATHE

Alterity Therapeutics Limited (ATHE) ESG Analysis Analysis (2026)

Invetso Score: 5.7/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

ATHE’s disclosed environmental profile appears limited versus larger peers, which constrains comparability and suggests weaker transparency on emissions, energy use, and climate targets.

The absence of reported R&D intensity and gross margin data in the provided metrics reduces evidence of resource-efficiency initiatives relative to peers with more complete sustainability disclosure.

Very low leverage can indirectly support environmental resilience by lowering balance-sheet pressure, but it does not itself indicate superior environmental management versus peers.

No material environmental controversies were provided, so the main peer-relative issue is disclosure depth rather than a clearly adverse operating footprint.

Social

Score:

ATHE’s social positioning appears broadly neutral versus peers because the provided data do not show clear advantages in workforce, safety, or customer-related ESG practices.

Zero stock-based compensation to revenue may indicate limited dilution pressure, but it does not by itself demonstrate stronger employee alignment or retention than peers.

The lack of disclosed social metrics such as turnover, injury rates, or diversity limits confidence that ATHE is outperforming peers on human-capital management.

No major social controversies were provided, so the peer-relative assessment is driven more by sparse disclosure than by evidence of strong social leadership.

Governance

Score:

ATHE’s very low debt-to-equity ratio suggests conservative capital structure discipline, which can reduce creditor pressure and support governance stability versus more leveraged peers.

Net debt to EBITDA remains modest, indicating manageable balance-sheet risk and less governance strain from refinancing or covenant pressure than highly levered peers.

However, the provided metrics do not show board independence, audit quality, or shareholder-rights practices, limiting evidence of stronger governance than peers.

Zero stock-based compensation to revenue may reduce compensation-related governance concerns, but the absence of broader disclosure keeps the overall governance edge modest.

Overall Score

Score:

ATHE appears broadly average versus peers, with conservative leverage supporting governance, but limited ESG disclosure prevents a stronger relative assessment.

Score Driver: Limited ESG Disclosure Depth Across Environmental And Social Metrics

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Alterity Therapeutics Limited. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →